Table 1 Demographic and clinicopathological characteristics of AML patients
From: Interleukin-4 gene intron 3 VNTR polymorphism in adult acute myeloid leukemia
Variables | AML patient (n = 60) |
|---|---|
Age (years), Mean ± SD | 43.1 ± 14.3 |
Sex, n (%) | |
Male | 42 (70) |
Female | 18 (30) |
Extramedullary involvement, n (%) | |
Positive | 34 (56.7) |
Negative | 26 (43.3) |
TLC (× 103/µL), Median (IQR) | 19.5 (5.8–58) |
Hemoglobin (g/dL), mean ± SD | 7.5 ± 2.2 |
Platelets (× 103/µL), Median (IQR) | 40.5 (15–79) |
PB blasts (%), Median (IQR) | 32 (5–63) |
Initial BM blasts (%), Median (IQR) | 69 (50–85) |
FAB subtype, n (%) | |
M0 | 3 (5.0) |
M1 | 12 (20) |
M2 | 32 (53.3) |
M4 | 11 (18.3) |
M5 | 0 (0.0) |
M6 | 0 (0.0) |
M7 | 2 (3.3) |
Immunophenotyping, n (%) | |
HLA-DR | 53 (88.3) |
CD34 | 49 (81.7) |
MPOX | 50 (83.3) |
Cytogenetic risk groups, n (%) | |
Favorable | 7 (11.66) |
Intermediate | 38 (63.33) |
Poor | 5 (8.33) |
NA* | 10 (16.66) |